About: Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
Creator	Barvaliya, Manish Kevadiya, Bhavesh Lal Bhalla, Hira Patel, Parvati Patel, Tejas
Source	Medline; PMC
abstract	Hydroxychloroquine has been promoted for its use in treatment of COVID-19 patients based on in-vitro evidences. We searched the databases to include randomized and observational studies evaluating the effect of Hydroxychloroquine on mortality in COVID-19 patients. The outcome was summarized as odds ratios (OR) with a 95% confidence interval (CI).We used the inverse-variance method with a random effect model and assessed the heterogeneity using I(2) test. We used ROBINS-I tool to assess methodological quality of the included studies. We performed the meta-analysis using ‘Review manager software version 5.3’. We identified 6 observationalstudies satisfying the selection criteria. In all studies, Hydroxychloroquine was given as add on to the standard care and effect was compared with the standard care alone. A pooled analysis observed 251 deaths in 1331 participants of the Hydroxychloroquine arm and 363 deaths in 1577 participants of the control arm. There was no difference in odds of mortality events amongst Hydroxychloroquine and supportive care arm [1.25 (95% CI: 0.65, 2.38); I(2) = 80%]. A similar trend was observed with moderate risk of bias studies [0.95 (95% CI: 0.44, 2.06); I(2) = 85%]. The odds of mortality were significantly higher in patients treated with Hydroxychloroquine + Azithromycin than supportive care alone [2.34 (95% CI: 1.63, 3.34); I(2) = 0%]. A pooled analysis of recently published studies suggests no additional benefit for reducing mortality in COVID-19 patients when Hydroxychloroquine is given as add-on to the standard care. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11481-020-09930-x) contains supplementary material, which is available to authorized users.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1007/s11481-020-09930-x
bibo:pmid	32519281
has license	no-cc
sha1sum (hex)	3c34db907062ec0e6784b4a3c32e2a3af7bda316
schema:url	https://doi.org/10.1007/s11481-020-09930-x
resource representing a document's title	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review
has PubMed Central identifier	PMC7280684
has PubMed identifier	32519281
schema:publication	J Neuroimmune Pharmacol
resource representing a document's body	covid:3c34db907062ec0e6784b4a3c32e2a3af7bda316#body_text
is schema:about of	named entity 'test' named entity 'observed' named entity 'patients' named entity 'COVID-19' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'Care' named entity 'BASED' named entity 'SUPPORTIVE CARE' named entity 'OBSERVED' named entity 'OUTCOME' named entity 'mortality' named entity 'mortality' named entity 'Hydroxychloroquine' named entity 'in-vitro' named entity 'observational studies' named entity 'control arm' named entity 'mortality' named entity 'studies' named entity 'selection criteria' named entity 'published' named entity 'participants' named entity 'random effect' named entity 'Hydroxychloroquine' named entity 'observational studies' named entity 'supportive care' named entity '2.06' named entity 'Hydroxychloroquine' named entity 'meta-analysis' named entity 'COVID' named entity 'COVID-19' named entity 'COVID' named entity 'COVID' named entity 'heterogeneity' named entity 'US FDA' named entity 'double blind' named entity 'observational studies' named entity 'sensitivity analysis' named entity 'supportive care' named entity 'erythematous' named entity 'cardiovascular diseases' named entity 'Hydroxychloroquine' named entity 'Hydroxychloroquine' named entity 'toxicity' named entity 'COVID' named entity 'cytokines' named entity 'animal studies' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'randomized controlled trials' named entity 'Azithromycin' named entity 'control arm' named entity 'Hydroxychloroquine' named entity 'Hydroxychloroquine' named entity 'Azithromycin' named entity 'lupus' named entity 'supportive care' named entity 'supportive care' named entity 'toxicity' named entity 'QT interval prolongation' named entity 'Ramireddy' named entity 'Chinese study' named entity 'observational studies' named entity 'supportive care' named entity 'cardiovascular diseases' named entity 'co-morbidities' named entity 'mechanical ventilation' named entity 'follow-up' named entity 'Hydroxychloroquine' named entity 'supportive care' named entity 'invitro' named entity '11.0' named entity 'Hydroxychloroquine' named entity 'supportive care' named entity 'Azithromycin' named entity 'COVID' named entity 'Hydroxychloroquine' named entity 'emergency department'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software